Marshall Wace’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Marshall Wace’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-602	Closed	-$28K	–	4119
2021 Q4	$28K	Buy	+602	New	+$28.5K	﹤0.01%	3667

Other funds holding XPH

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

FFM

Fullerton Fund Management Singapore $1.56B AUM 88.19% 1-Year Est. Return

Marshall Wace's XPH Position: Q1 2022 in Review

Marshall Wace sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q1 2022, closing a stake of 602 shares — an estimated $28K sold.

Marshall Wace first reported a position in XPH in Q4 2021 and held it in 1 quarter. The position peaked at $28K in Q4 2021. 69 funds tracked by Wall St. Rank hold XPH as of Q1 2022.

Marshall Wace reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q1 2022 after selling out during the quarter.
Marshall Wace sold 602 State Street SPDR S&P Pharmaceuticals ETF shares in Q1 2022, an estimated $28K.
Marshall Wace first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2021 and held it in 1 quarter.
Marshall Wace's State Street SPDR S&P Pharmaceuticals ETF position peaked at $28K in Q4 2021.
69 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.